Opinion|Videos|July 24, 2024
Phase II and KEYNOTE B-61: Comparative Analysis of Cancer Trials
Author(s)Martin H. Voss, MD, Moshe Ornstein, MD, MA
Medical experts compare the updated results of a Phase II trial and KEYNOTE B-61, both presented at ASCO 2024, giving a comprehensive overview of these pivotal studies.
Advertisement
Episodes in this series
Advertisement
Related to this article
Erik Bengtsen, MD, discussed meaning-centered therapy at the bedside, framing psychiatry referrals, and a more humanistic approach to care.
Erik Bengtsen, MD, described what sets psycho-oncology apart and how clinicians can open conversations on body image and sexual health.
Erik Bengtsen, MD, explained how antidepressants may improve quality of life and how he typically works with patients who decline favorable treatment.
Erik Bengtsen, MD, shares a key depression screening question and explains when oncologists can start a low-dose antidepressant.
Al-Ola A. Abdallah, MD, explains a possible biological reason IMiD holding therapy benefited ide-cel but not cilta-cel recipients.
Advertisement
Advertisement
Trending on CancerNetwork
1
INTerpath-001 Data Detail Survival, Subgroup, and Safety Findings in Melanoma
2
Tarlatamab Maintenance Combo Extends Survival in Extensive-Stage SCLC
3
Belantamab Mafodotin Combo Yields High MRD Negativity in NDMM
4
Apalutamide/ADT Improves EFS vs Surgery Alone in High-Risk Prostate Cancer
5